SCHEDULE 13G: RTW Investments Discloses 7.9% Stake in uniQure N.V.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 7.9% beneficial ownership stake in uniQure N.V. as of March 31, 2025, through a Schedule 13G filing.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in uniQure N.V.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 4,265,428 Ordinary Shares of uniQure N.V.
• This ownership represents 7.9% of uniQure N.V.'s outstanding Ordinary Shares.
• The percentage is calculated based on 54,076,880 shares outstanding as of February 24, 2025, as reported in uniQure N.V.'s Annual Report on Form 10-K filed on February 27, 2025.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of uniQure N.V.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable investment firm like RTW Investments is generally viewed positively as it signals institutional confidence in the company's prospects, although it is a routine regulatory filing and does not imply active management involvement.

Positives

• The disclosure of a significant 7.9% stake by RTW Investments, a specialized healthcare investment firm, indicates institutional confidence and potential long-term interest in uniQure N.V.
• The investment by a reputable firm like RTW Investments may attract further institutional interest and potentially stabilize or boost investor sentiment towards uniQure N.V.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing the control of the issuer, mitigating concerns about potential activist investor actions.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding uniQure N.V.'s future performance or strategic direction.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

uniQure N.V. is a biotechnology company, and the investment by RTW Investments, a firm specializing in healthcare and life sciences, aligns with typical institutional investment strategies in the sector. Such filings indicate ongoing interest from specialized funds in companies within their domain.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, which is a common regulatory requirement for institutional investors acquiring more than 5% of a company's shares.
• The 7.9% stake is a significant, but not controlling, position, typical for passive institutional investments in the biotech sector where firms like RTW Investments often build positions in promising companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be perceived positively, potentially boosting investor confidence and attracting further investment.
• Company Management: The filing indicates continued institutional interest in uniQure N.V. without suggesting any intent to influence control, which may be viewed favorably by current management.

Next Steps

• No specific future actions or milestones for uniQure N.V. are mentioned in this beneficial ownership disclosure.

Key Dates

Recommendation

Keywords

uniQure N.V., RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, ordinary shares, institutional investment, biotechnology, healthcare investment